PFE (Pfizer) Cash Flow from Financing : $-17,140 Mil (TTM As of Dec. 2024)

View and export this data going back to 1951. Start your Free Trial

What is Pfizer Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2024, Pfizer paid $0 Mil more to buy back shares than it received from issuing new shares. It spent $2,720 Mil paying down its debt. It paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent $2,380 Mil paying cash dividends to shareholders. It spent $14 Mil on other financial activities. In all, Pfizer spent $5,114 Mil on financial activities for the three months ended in Dec. 2024.

Pfizer Cash Flow from Financing Historical Data

The historical data trend for Pfizer's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Cash Flow from Financing Chart

Pfizer Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash Flow from Financing

Get a 7-Day Free Trial

-9,649.00

-9,816.00

-14,834.00

26,066.00

-17,140.00

Pfizer Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash Flow from Financing	Get a 7-Day Free Trial															5,442.00	-4,931.00	-2,459.00	-4,636.00	-5,114.00

Pfizer Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Pfizer's Cash from Financing for the fiscal year that ended in Dec. 2024 is calculated as:

	Cash Flow from Financing		(A: Dec. 2024 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	-7159	+	0	+	-9512	+	-469
=	-17,140

Pfizer's Cash from Financing for the quarter that ended in Dec. 2024 is:

	Cash Flow from Financing		(Q: Dec. 2024 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	-2720	+	0	+	-2380	+	-14
=	-5,114

Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17,140 Mil.

Pfizer (NYSE:PFE) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Pfizer's issuance of stock for the three months ended in Dec. 2024 was $0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Pfizer's repurchase of stock for the three months ended in Dec. 2024 was $0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Pfizer's net issuance of debt for the three months ended in Dec. 2024 was $-2,720 Mil. Pfizer spent $2,720 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Pfizer's net issuance of preferred for the three months ended in Dec. 2024 was $0 Mil. Pfizer paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Pfizer's cash flow for dividends for the three months ended in Dec. 2024 was $-2,380 Mil. Pfizer spent $2,380 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Pfizer's other financing for the three months ended in Dec. 2024 was $-14 Mil. Pfizer spent $14 Mil on other financial activities.

Pfizer Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Pfizer's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Pfizer Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (NYSE:PFE) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

PFE:Peru PFE:Mexico PFE_KZ:Kazakhstan 1PFE:Italy PFEd:UK 0Q1N:UK PFE:Germany PFE:Chile PFE:Canada PFIZ34:Brazil PFE:Bulgaria PFE:Austria PFE:Argentina

Address

66 Hudson Boulevard East, New York, NY, USA, 10001-2192

Website

https://www.pfizer.com

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Executives

Ronald E Blaylock	director
Scott Gottlieb	director	MOLECULAR INSIGHT PHARMACEUTICALS, 160 SECOND STREET, CAMBRIDGE MA 02142
Jennifer B. Damico	officer: SVP & Controller	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Christoffel Boshoff	officer: Executive Vice President	66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Payal Sahni	officer: Executive Vice President	ATTN: PFIZER CORP. SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017
Carapezzi William R Jr	officer: Executive Vice President	600 MOUNTAIN AVENUE, MURRAY HILL NJ 07921
Douglas M Lankler	officer: Senior Vice President	PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Mikael Dolsten	officer: Senior Vice President	5 GIRALDA FARMS, MADISON NJ 07940
David M Denton	officer: Chief Financial Officer & EVP	1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117
William Pao	officer: Executive Vice President	C/O CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Michael Mcdermott	officer: Executive Vice President	C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, 235 EAST 42ND STREET NY 10017
Rady A Johnson	officer: Executive Vice President	PFIZER INC. ATTN CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Alexander R Mackenzie	officer: Executive Vice President	C/O PFIZER CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Sally Susman	officer: Senior Vice President	767 FIFTH AVE, EOTIC LAWDER CORP, NEW YORK NY 10153
Angela Hwang	officer: Group President	235 EAST 42ND STREET, ATTN: CORPORATE SECRETARY, NEW YORK NY 10017